IL6 and Coats disease: In fact, a study by Feng et al. suggested that anti-VEGF therapy may actually have higher efficacy in younger patients26, since paediatric Coats’ disease patients were shown to have higher aqueous concentrations of VEGF, interleukin (IL)-6 (a proinflammatory cytokine promoting increased vascular permeability), and IL-1ß (role in angiogenic diseases) than healthy controls.